Onapristone

Drug Profile

Onapristone

Alternative Names: AR-18; IVV-1001; Onapristone extended-release; ZK 299; ZK 98299

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Glucocorticoid receptor antagonists; Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Breast cancer; Endometrial cancer; Endometriosis; Ovarian cancer; Pregnancy; Uterine cancer

Most Recent Events

  • 02 Jun 2017 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase I/II trial in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Aug 2016 Phase-II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 16 Aug 2016 Phase-II clinical trials in Prostate cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top